<DOC>
	<DOCNO>NCT01777958</DOCNO>
	<brief_summary>This observational study evaluate efficacy , safety patient report quality life palliative first-line Perjeta ( pertuzumab ) combination Herceptin ( trastuzumab ) patient HER2-positive advanced breast cancer ( metastatic locally recurrent , inoperable ) relapse complete adjuvant Herceptin therapy . Additionally , information selection criterion breast cancer patient treat first-line Perjeta , Herceptin chemotherapy treatment duration collect analyzed . Data collect eligible patient 20 month treatment 24 month follow-up .</brief_summary>
	<brief_title>HELENA Study : An Observational Study Perjeta ( Pertuzumab ) First-Line Treatment Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female adult patient , &gt; /= 18 year age HER2positive advance breast cancer ( metastatic locally recurrent , inoperable ) relapse complete adjuvant Herceptin therapy Indication firstline treatment Perjeta combination Herceptin chemotherapy accord Summary Product Characteristics Prior Herceptin therapy systemic adjuvant treatment ( postoperative treatment potentially curable set ) ; additional upfront neoadjuvant Herceptin therapy allow No prior chemotherapy and/or immunotherapy advance ( metastatic locally recurrent , inoperable ) HER2positive breast cancer Pregnant breastfeed woman Contraindications Perjeta , Herceptin concomitant chemotherapy accord Summary Product Characteristics No Herceptin treatment early breast cancer adjuvant set</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>